Entity

Time filter

Source Type

Fremont, CA, United States

Patent
Zosano Pharma | Date: 2014-08-22

There is provided glucagon formulations suitable for preparing coatings on microneedle patches for the transdermal delivery of glucagon. The coated patches may be used for the treatment of low blood sugar in diabetic patients. Also provided are glucagon loaded patches, methods for their preparation, and methods of their use.


News Article | November 15, 2007
Site: venturebeat.com

Vaxart receives $3.3M for oral vaccines — San Francisco’s Vaxart, a biotech developing novel adenovirus-based vaccines, raised $2.7 million in a first funding round. Vaxart also received a $600,000 small-business innovation grant from the NIH to assist in developing the company’s vaccine platform. Vaxart’s vaccine technology involves a non-replicating adenovirus engineered to produce a particular bacterial or viral protein, or antigen, which stimulates an immune response. The vaccine, which consists of the adenovirus and an “adjuvant” designed to enhance the immune response, is packaged in a capsule that can be taken by mouth. Vaccines that depend on viral “vectors” like adenovirus are promising because they can produce immunity without the need to rely on attenuated or killed disease virus. When injected, however, such vaccines frequently stimulate an immune reaction to the adenovirus itself, which can negate the effect of the vaccine or subsequent booster shots. Vaxart believes that oral delivery can sidestep that problem. The company’s early candidates include vaccines against avian flu, seasonal flu, and biowarfare agents. Investors in the round included Quantum Technology Partners, Life Science Angels, Bay Partners and Sand Hill Angels. Reliant Tech postpones IPO — Reliant Technologies, the Mountain View, Calif., maker of laser skin treatments, postponed its IPO indefinitely, PE Hub reports. The medical-device maker had previously filed to raise up to $86.5 million in an offer of 5.4 million shares. Reliant Tech’s postponement comes just a day after EnteroMedics, a maker of obesity-control devices, almost halved its IPO pricing. Until recently, device makers had lived a charmed life where IPOs were concerned, but it’s beginning to look as though market turmoil may be taking its toll on this sector as well. Our previous coverage of the company is here and here. On the other hand, at least IPO investors won’t get the company confused with Reliant Pharmaceuticals anymore. N Spine acquired by Synthes for $30M — N Spine, a San Diego maker of spinal devices, was acquired by Switzerland’s Synthes for $30 million. The release is here. N Spine shareholders also stand to receive an additional $45 million in milestone payments if development of the company’s products proceeds as planned. Our previous coverage of N Spine’s fundraising is here. Zosano Pharma raises $45M for needle-free drugs — Fremont, Calif.-based Zosano Pharma, a specialty pharma working on needle-free drug delivery, raised $45 million in the second half of its initial venture funding. The company said it has now raised a total of $90 million. Our previous coverage of the company, which used to be called Macroflux, is here (last item). Investors included New Enterprise Associates, Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. Zosano’s lead candidate is a patch for delivering the drug PTH through the skin to treat osteoporosis.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zxjf6n/global_insulin) has announced the addition of the "Global Insulin Patch Market Opportunity Analysis" report to their offering. Highly advanced technology like ultrasound and iontophoresis are being used for the development of modern insulin patches. Depending upon the type of technique, their prices may vary which may be out of reach of several patients. In long-term, it would be considered as inexpensive but high upfront cost may deter some diabetic patients. Benefits like greater control over blood glucose levels and ease of utilization are one of the most significant benefits of these technologies. It is expected that investigators would also explore the techniques like electroporation, thermal ablation and microdermabrasion for making insulin patches. These techniques are expected to increase the cost effectiveness due to which their market penetration would increase. In coming years, it is expected that investigators would be able to come forth with insulin patches having higher pharmacological benefits with lesser prices. Besides this, newer modalities are also expected to be developed due to which more sales are expected to be generated. Development of insulin patches are expected to pave the path for the development of large molecule based transdermal patches. This is going to be a major technological success due to which large number of patients would get more therapeutic benefits. Due to increased indications, more revenues are expected to generate from this field. Both molecules and formulations have to be revisited that will lead to new innovations. Moreover, pharmaceutical companies engaged in the production of insulin patches may venture in other diseases segment by using same technology. Insulin patches have yet not made place in global market but they will definitely encourage the other pharmaceutical companies to follow the lead. Pharmaceutical companies are expected to launch the first insulin patch in global market in next few years.


Patent
Zosano Pharma | Date: 2014-07-30

A low-profile applicator, and a method of manufacturing and use thereof, for impacting microneedles against the stratum corneum of a person having a housing, a diaphragm member having the microneedles, a folding member having interlinking members that hinge-ably rotate with a force member, operatively attached thereto, between a resting position and an extended position. The folding member translates energy stored within the force member when release while retaining the force member in an energized state when in the resting position.


(http://www.researchandmarkets.com/research/7qn2gf/global_insulin) has announced the addition of the "Global Insulin Patch Market Opportunity Analysis" report to their offering. Highly advanced technology like ultrasound and iontophoresis are being used for the development of modern insulin patches. Depending upon the type of technique, their prices may vary which may be out of reach of several patients. In long-term, it would be considered as inexpensive but high upfront cost may deter some diabetic patients. Benefits like greater control over blood glucose levels and ease of utilization are one of the most significant benefits of these technologies. It is expected that investigators would also explore the techniques like electroporation, thermal ablation and microdermabrasion for making insulin patches. These techniques are expected to increase the cost effectiveness due to which their market penetration would increase. In coming years, it is expected that investigators would be able to come forth with insulin patches having higher pharmacological benefits with lesser prices. Besides this, newer modalities are also expected to be developed due to which more sales are expected to be generated. Development of insulin patches are expected to pave the path for the development of large molecule based transdermal patches. This is going to be a major technological success due to which large number of patients would get more therapeutic benefits. Due to increased indications, more revenues are expected to generate from this field. Both molecules and formulations have to be revisited that will lead to new innovations. Moreover, pharmaceutical companies engaged in the production of insulin patches may venture in other diseases segment by using same technology. Insulin patches have yet not made place in global market but they will definitely encourage the other pharmaceutical companies to follow the lead. Pharmaceutical companies are expected to launch the first insulin patch in global market in next few years. "Global Insulin Patch Market Opportunity Analysis" Report Highlights: - Introduction to Insulin Patch - Mechanism Iontophoresis, Ultrasonic & Microneedle Insulin Patch - Global Insulin Patch Market Analysis - Global Insulin Patch Clinical Pipeline by Company, Indication & Phase - Global Insulin Patch Clinical Pipeline: 9 Patches - Highest Phase of Insulin Patch Development: Phase-II - Insulin Patch Patent Analysis Key Topics Covered: 1. Introduction to Insulin Patch 2. Comparison between Insulin Patches & Other Insulin Modalities 3. Mechanism of Insulin Patches 4. Emerging Trends in Insulin Delivery 5. Global Insulin Patch Market Analysis 6. Global Insulin Patch Market Dynamics 7. Future Prospects of Insulin Patch Market 8. Global Insulin Patch Clinical Pipeline by Company, Indication & Phase 9. Discontinued Insulin Patch in Clinical Pipeline 10. Competitive Landscape - Dermisonics - Encapsulation Systems - Encapsulife - Mesoblast - NeurogesX - NOLabs AB - Novo Nordisk - Phosphagenics - Relmada Therapeutics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/7qn2gf/global_insulin

Discover hidden collaborations